+7 (777) 001 44 99
Қазақша
Русский
English
Қазақша
Русский
English
ПОДЕЛИТЬСЯ
Kazakhstan scientists have developed a technology to produce validol with low content of impurities, Khakim Suyerbayev, project manager and professor of the Department of Physical Chemistry, Catalysis and Oil Chemistry of Al-Farabi Kazakh State University told Tengrinews.kz. Validol is a medicine that produces a sedative effect, and has a moderate reflex and vascular dilative action caused by the stimulation of sensitive nerve endings. At sublingual administration the effect is produced in five minutes and 70 % of the preparation is released in 3 minutes. It is used in cases of heart disease (cardialgia), angina, motion sickness, nausea, vomiting when seasick or airsick, hysteria, nervousness and headaches from taking nitrates. According to the scientist, validol is currently imported to Kazakhstan from Russia and Ukraine. The Kazakhstan technology for production of the medicine called Novovalidol allows to decrease its self-cost 3-4 times. According to Suyerbayev, the traditional technologies includes two production stages, while Novovalidol can be produced in one stage. The scientist told that the quality of Kazakhstan-made medicine exceeds its foreign equivalents. The traditional validol has 11 types of impurities with the total content of around 8 percent. Novovalidol contains only three types of impurities that reach the total of 1-1.5 percent. Its pharmacological properties are as good as traditional validol. Suyerbayev added that production of Novovalidol practically does not effect the environment, while the process of production of common validol accumulates a huge amount of hazardous wastes. But despite of the promise of the project, there are still no investors ready to spend money on setting up production of Novovalidol. Suyerbayev noted that organization of the industrial production of the new medicine would not require big investments, it can be established in an existing pharmaceutical company. High quality and low self-cost of Novovalidol make it highly-competitive product for export. Potential importers of Novovalidol are all countries of the former Soviet space and Central and South-East Asia. By Dmitriy Khegai
Kazakhstan scientists have developed a technology to produce validol with low content of impurities, Khakim Suyerbayev, project manager and professor of the Department of Physical Chemistry, Catalysis and Oil Chemistry of Al-Farabi Kazakh State University told Tengrinews.kz.
Validol is a medicine that produces a sedative effect, and has a moderate reflex and vascular dilative action caused by the stimulation of sensitive nerve endings. At sublingual administration the effect is produced in five minutes and 70 % of the preparation is released in 3 minutes. It is used in cases of heart disease (cardialgia), angina, motion sickness, nausea, vomiting when seasick or airsick, hysteria, nervousness and headaches from taking nitrates.
According to the scientist, validol is currently imported to Kazakhstan from Russia and Ukraine. The Kazakhstan technology for production of the medicine called Novovalidol allows to decrease its self-cost 3-4 times. According to Suyerbayev, the traditional technologies includes two production stages, while Novovalidol can be produced in one stage.
The scientist told that the quality of Kazakhstan-made medicine exceeds its foreign equivalents. The traditional validol has 11 types of impurities with the total content of around 8 percent. Novovalidol contains only three types of impurities that reach the total of 1-1.5 percent. Its pharmacological properties are as good as traditional validol.
Suyerbayev added that production of Novovalidol practically does not effect the environment, while the process of production of common validol accumulates a huge amount of hazardous wastes. But despite of the promise of the project, there are still no investors ready to spend money on setting up production of Novovalidol.
Suyerbayev noted that organization of the industrial production of the new medicine would not require big investments, it can be established in an existing pharmaceutical company. High quality and low self-cost of Novovalidol make it highly-competitive product for export. Potential importers of Novovalidol are all countries of the former Soviet space and Central and South-East Asia.
By Dmitriy Khegai
